NEJM at ESMO — Phase 3 Trial of Cabozantinib in Advanced Neuroendocrine Tumors
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
NEJM at ESMO — Phase 3 Trial of Cabozantinib in Advanced Neuroendocrine Tumors
In this audio interview, Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research being presented at the 2024 European Society of...
Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors
Cabozantinib, as compared with placebo, doubled median progression-free survival in patients with extrapancreatic neuroendocrine tumors and tripled it in those with pancreatic neuroendocrine tumors.
The...
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
NEJM at ESMO — Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
